TY - JOUR
T1 - Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma
T2 - Correlation with the clinicopathologic features and patient outcome
AU - PYO, Sung Woon
AU - HASHIMOTO, Mitsuyoshi
AU - KIM, Young Sill
AU - KIM, Chang Hyen
AU - LEE, Sang Hwa
AU - JOHNSON, Keith R.
AU - WHEELOCK, Margaret J.
AU - PARK, Je Uk
PY - 2007/1
Y1 - 2007/1
N2 - Purpose: Alteration of cadherin expression is associated with the loss of cellular differentiation, the acquisition of an invasive phenotype and a poor prognosis in many types of cancer. This study aimed to evaluate the immunoreactivity of E-, P- and N-cadherins (cad) in oral squamous cell carcinoma and to correlate their expression with clinicopathological features and clinical outcome. The interaction between the cadherins was also investigated. Methods: A total of 71 tissue samples were examined by immunohistochemical methods on paraffin sections using specific antibodies. Results: In the primary lesions and lymph node metastases, the immunoreactivity of E-cad was reduced and P-cad was over-expressed, but the expression of N-cad was negative (p<0.001, 0.01 and 0.05, respectively). The reduced primary E-cad expression was related to the invasion pattern and lymph node metastasis (p=0.046 and 0.037, respectively). However, the expression of cadherins did not appear to differ significantly in relation to the histological grade, invasion, tumour size, stage of oral SCC or tumour recurrence. A much greater reduction in the expression of E-cad was found in the positive N-cadherin group (p=0.008). Nonetheless, cadherin expression was not significantly associated with failure-free survival or overall survival in this experiment subset. Conclusion: The reduced E-cad expression and the aberrant N-cad expression are closely associated with each other in oral cancer cases, and this suggests that cadherin switching from E. cad to N. cad may play a critical role in cancer development and metastasis.
AB - Purpose: Alteration of cadherin expression is associated with the loss of cellular differentiation, the acquisition of an invasive phenotype and a poor prognosis in many types of cancer. This study aimed to evaluate the immunoreactivity of E-, P- and N-cadherins (cad) in oral squamous cell carcinoma and to correlate their expression with clinicopathological features and clinical outcome. The interaction between the cadherins was also investigated. Methods: A total of 71 tissue samples were examined by immunohistochemical methods on paraffin sections using specific antibodies. Results: In the primary lesions and lymph node metastases, the immunoreactivity of E-cad was reduced and P-cad was over-expressed, but the expression of N-cad was negative (p<0.001, 0.01 and 0.05, respectively). The reduced primary E-cad expression was related to the invasion pattern and lymph node metastasis (p=0.046 and 0.037, respectively). However, the expression of cadherins did not appear to differ significantly in relation to the histological grade, invasion, tumour size, stage of oral SCC or tumour recurrence. A much greater reduction in the expression of E-cad was found in the positive N-cadherin group (p=0.008). Nonetheless, cadherin expression was not significantly associated with failure-free survival or overall survival in this experiment subset. Conclusion: The reduced E-cad expression and the aberrant N-cad expression are closely associated with each other in oral cancer cases, and this suggests that cadherin switching from E. cad to N. cad may play a critical role in cancer development and metastasis.
KW - E-cadherin, P-cadherin, N-cadherin, oral squamous cell carcinoma, survival, cadherin switching, metastasis
UR - http://www.scopus.com/inward/record.url?scp=33847135187&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847135187&partnerID=8YFLogxK
U2 - 10.1016/j.jcms.2006.11.004
DO - 10.1016/j.jcms.2006.11.004
M3 - Article
C2 - 17296306
AN - SCOPUS:33847135187
SN - 1010-5182
VL - 35
SP - 1
EP - 9
JO - Journal of Cranio-Maxillofacial Surgery
JF - Journal of Cranio-Maxillofacial Surgery
IS - 1
ER -